{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T07:12:19Z","timestamp":1782976339896,"version":"3.54.5"},"reference-count":123,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["019R1A2C1009231"],"award-info":[{"award-number":["019R1A2C1009231"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012145","name":"Shenyang Normal University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012145","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.bcp.2019.113698","type":"journal-article","created":{"date-parts":[[2019,11,7]],"date-time":"2019-11-07T11:30:18Z","timestamp":1573126218000},"page":"113698","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Epigenetic mechanisms underlying the therapeutic effects of HDAC inhibitors in chronic myeloid leukemia"],"prefix":"10.1016","volume":"173","author":[{"given":"Manon","family":"Lernoux","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0550-9538","authenticated-orcid":false,"given":"Michael","family":"Schnekenburger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Dicato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0115-4725","authenticated-orcid":false,"given":"Marc","family":"Diederich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.bcp.2019.113698_b0005","doi-asserted-by":"crossref","first-page":"581","DOI":"10.2217\/epi.11.73","article-title":"Epigenomics of leukemia: from mechanisms to therapeutic applications","volume":"3","author":"Florean","year":"2011","journal-title":"Epigenomics"},{"issue":"10","key":"10.1016\/j.bcp.2019.113698_b0010","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/j.mayocp.2015.08.010","article-title":"Diagnosis and Treatment of Chronic Myeloid Leukemia in 2015","volume":"90","author":"Thompson","year":"2015","journal-title":"Mayo Clinic proceedings"},{"issue":"3","key":"10.1016\/j.bcp.2019.113698_b0015","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1002\/ajh.25011","article-title":"Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring","volume":"93","author":"Jabbour","year":"2018","journal-title":"Am J Hematol"},{"issue":"5","key":"10.1016\/j.bcp.2019.113698_b0020","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1158\/1055-9965.EPI-13-0093","article-title":"Lifestyle and dietary factors in relation to risk of chronic myeloid leukemia in the NIH-AARP Diet and Health Study","volume":"22","author":"Kabat","year":"2013","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"5","key":"10.1016\/j.bcp.2019.113698_b0025","doi-asserted-by":"crossref","first-page":"541","DOI":"10.3324\/haematol.2015.139337","article-title":"Chronic myeloid leukemia: reminiscences and dreams","volume":"101","author":"Mughal","year":"2016","journal-title":"Haematologica"},{"issue":"56","key":"10.1016\/j.bcp.2019.113698_b0030","doi-asserted-by":"crossref","first-page":"8652","DOI":"10.1038\/sj.onc.1206094","article-title":"BCR\/ABL genes and leukemic phenotype: from molecular mechanisms to clinical correlations","volume":"21","author":"Pane","year":"2002","journal-title":"Oncogene"},{"issue":"4","key":"10.1016\/j.bcp.2019.113698_b0035","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1158\/1078-0432.CCR-10-1613","article-title":"Molecular pathways: BCR-ABL","volume":"18","author":"Cilloni","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.bcp.2019.113698_b0040","first-page":"18","article-title":"Strategies to circumvent the T315I gatekeeper mutation in the Bcr-Abl tyrosine kinase","volume":"2","author":"Bose","year":"2013","journal-title":"Leuk Res Rep"},{"issue":"9976","key":"10.1016\/j.bcp.2019.113698_b0045","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/S0140-6736(13)62120-0","article-title":"Chronic myeloid leukaemia","volume":"385","author":"Apperley","year":"2015","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.bcp.2019.113698_b0050","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13045-018-0624-2","article-title":"Past, present, and future of Bcr-Abl inhibitors: from chemical development to clinical efficacy","volume":"11","author":"Rossari","year":"2018","journal-title":"J Hematol Oncol"},{"issue":"7","key":"10.1016\/j.bcp.2019.113698_b0055","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/nchembio799","article-title":"Rational design of inhibitors that bind to inactive kinase conformations","volume":"2","author":"Liu","year":"2006","journal-title":"Nat Chem Biol"},{"issue":"5486","key":"10.1016\/j.bcp.2019.113698_b0060","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1126\/science.289.5486.1938","article-title":"Structural mechanism for STI-571 inhibition of abelson tyrosine kinase","volume":"289","author":"Schindler","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.bcp.2019.113698_b0065","article-title":"The Interface between BCR-ABL-Dependent and -Independent Resistance Signaling Pathways in Chronic Myeloid Leukemia","volume":"2012","author":"Nestal de Moraes","year":"2012","journal-title":"Leuk Res Treatment"},{"issue":"6","key":"10.1016\/j.bcp.2019.113698_b0070","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.blre.2011.09.001","article-title":"Managing resistance in chronic myeloid leukemia","volume":"25","author":"Roychowdhury","year":"2011","journal-title":"Blood Rev"},{"issue":"6","key":"10.1016\/j.bcp.2019.113698_b0075","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s13238-015-0143-7","article-title":"Leukemia stem cells: the root of chronic myeloid leukemia","volume":"6","author":"Zhou","year":"2015","journal-title":"Protein Cell"},{"issue":"5","key":"10.1016\/j.bcp.2019.113698_b0080","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/nrc2126","article-title":"Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia","volume":"7","author":"Weisberg","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.bcp.2019.113698_b0085","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1756-8722-3-47","article-title":"First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib","volume":"3","author":"Wei","year":"2010","journal-title":"J Hematol Oncol"},{"issue":"5","key":"10.1016\/j.bcp.2019.113698_b0090","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.clinthera.2010.05.003","article-title":"Treatment options for patients with chronic myeloid leukemia who are resistant to or unable to tolerate imatinib","volume":"32","author":"Stein","year":"2010","journal-title":"Clin Ther"},{"issue":"3","key":"10.1016\/j.bcp.2019.113698_b0095","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1200\/JCO.2017.74.7162","article-title":"Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial","volume":"36","author":"Cortes","year":"2018","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.bcp.2019.113698_b0100","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s13045-018-0685-2","article-title":"Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: expert panel review","volume":"11","author":"Cortes","year":"2018","journal-title":"J Hematol Oncol"},{"issue":"9","key":"10.1016\/j.bcp.2019.113698_b0105","doi-asserted-by":"crossref","first-page":"847","DOI":"10.2174\/1568009617666171002142659","article-title":"Ponatinib: A Review of Efficacy and Safety","volume":"18","author":"Massaro","year":"2018","journal-title":"Curr Cancer Drug Targets"},{"issue":"37","key":"10.1016\/j.bcp.2019.113698_b0110","doi-asserted-by":"crossref","first-page":"5528","DOI":"10.1038\/sj.onc.1210619","article-title":"Chemistry of acetyl transfer by histone modifying enzymes: structure, mechanism and implications for effector design","volume":"26","author":"Hodawadekar","year":"2007","journal-title":"Oncogene"},{"issue":"8","key":"10.1016\/j.bcp.2019.113698_b0115","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/nrm3841","article-title":"The growing landscape of lysine acetylation links metabolism and cell signalling","volume":"15","author":"Choudhary","year":"2014","journal-title":"Nature reviews. Molecular cell biology"},{"key":"10.1016\/j.bcp.2019.113698_b0120","article-title":"The tale of protein lysine acetylation in the cytoplasm","volume":"2011","author":"Sadoul","year":"2011","journal-title":"Journal of biomedicine & biotechnology"},{"issue":"1","key":"10.1016\/j.bcp.2019.113698_b0125","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.biocel.2008.08.027","article-title":"Acetylation of non-histone proteins modulates cellular signalling at multiple levels","volume":"41","author":"Spange","year":"2009","journal-title":"The international journal of biochemistry & cell biology"},{"issue":"1","key":"10.1016\/j.bcp.2019.113698_b0130","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.canlet.2013.09.026","article-title":"Antiproliferative and proapoptotic activities of 4-hydroxybenzoic acid-based inhibitors of histone deacetylases","volume":"343","author":"Seidel","year":"2014","journal-title":"Cancer letters"},{"issue":"2","key":"10.1016\/j.bcp.2019.113698_b0135","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/cr.2013.151","article-title":"Protein post-translational modifications and regulation of pluripotency in human stem cells","volume":"24","author":"Wang","year":"2014","journal-title":"Cell research"},{"issue":"Pt 3","key":"10.1016\/j.bcp.2019.113698_b0140","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1042\/bj20021321","article-title":"Histone deacetylases (HDACs): characterization of the classical HDAC family","volume":"370","author":"de Ruijter","year":"2003","journal-title":"The Biochemical journal"},{"issue":"4","key":"10.1016\/j.bcp.2019.113698_b0145","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a018713","article-title":"Erasers of histone acetylation: the histone deacetylase enzymes","volume":"6","author":"Seto","year":"2014","journal-title":"Cold Spring Harbor perspectives in biology"},{"issue":"1","key":"10.1016\/j.bcp.2019.113698_b0150","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2217\/epi.14.69","article-title":"Histone deacetylase 6 in health and disease","volume":"7","author":"Seidel","year":"2015","journal-title":"Epigenomics"},{"issue":"1","key":"10.1016\/j.bcp.2019.113698_b0155","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jmb.2004.02.006","article-title":"Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis","volume":"338","author":"Gregoretti","year":"2004","journal-title":"Journal of molecular biology"},{"issue":"1","key":"10.1016\/j.bcp.2019.113698_b0160","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1002\/jcb.20179","article-title":"Regulation of histone deacetylase activities","volume":"93","author":"Sengupta","year":"2004","journal-title":"J Cell Biochem"},{"issue":"5","key":"10.1016\/j.bcp.2019.113698_b0165","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0962-8924(99)01536-6","article-title":"Histone deacetylases: transcriptional repression with SINers and NuRDs","volume":"9","author":"Ayer","year":"1999","journal-title":"Trends Cell Biol"},{"issue":"13","key":"10.1016\/j.bcp.2019.113698_b0170","doi-asserted-by":"crossref","first-page":"7202","DOI":"10.1073\/pnas.97.13.7202","article-title":"The histone deacetylase-3 complex contains nuclear receptor corepressors","volume":"97","author":"Wen","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.bcp.2019.113698_b0175","doi-asserted-by":"crossref","first-page":"139","DOI":"10.2217\/epi.13.73","article-title":"HDAC4: mechanism of regulation and biological functions","volume":"6","author":"Wang","year":"2014","journal-title":"Epigenomics"},{"issue":"9","key":"10.1016\/j.bcp.2019.113698_b0180","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1111\/j.1582-4934.2011.01321.x","article-title":"Class IIa HDACs: from important roles in differentiation to possible implications in tumourigenesis","volume":"15","author":"Clocchiatti","year":"2011","journal-title":"Journal of cellular and molecular medicine"},{"issue":"11","key":"10.1016\/j.bcp.2019.113698_b0185","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1016\/j.biochi.2012.05.012","article-title":"Chromatin-modifying agents in anti-cancer therapy","volume":"94","author":"Seidel","year":"2012","journal-title":"Biochimie"},{"issue":"6","key":"10.1016\/j.bcp.2019.113698_b0190","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1016\/j.bmcl.2008.02.025","article-title":"Probing the elusive catalytic activity of vertebrate class IIa histone deacetylases","volume":"18","author":"Jones","year":"2008","journal-title":"Bioorg Med Chem Lett"},{"issue":"44","key":"10.1016\/j.bcp.2019.113698_b0195","doi-asserted-by":"crossref","first-page":"17335","DOI":"10.1073\/pnas.0706487104","article-title":"Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases","volume":"104","author":"Lahm","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"10.1016\/j.bcp.2019.113698_b0200","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/nrc2657","article-title":"p21 in cancer: intricate networks and multiple activities","volume":"9","author":"Abbas","year":"2009","journal-title":"Nat Rev Cancer"},{"issue":"18","key":"10.1016\/j.bcp.2019.113698_b0205","doi-asserted-by":"crossref","first-page":"10014","DOI":"10.1073\/pnas.180316197","article-title":"Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation","volume":"97","author":"Richon","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"10.1016\/j.bcp.2019.113698_b0210","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1093\/emboj\/21.11.2672","article-title":"Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression","volume":"21","author":"Lagger","year":"2002","journal-title":"EMBO J"},{"issue":"2","key":"10.1016\/j.bcp.2019.113698_b0215","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/pros.20022","article-title":"Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer","volume":"59","author":"Halkidou","year":"2004","journal-title":"Prostate"},{"issue":"9","key":"10.1016\/j.bcp.2019.113698_b0220","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1158\/1535-7163.MCT-05-0480","article-title":"Valproate inhibition of histone deacetylase 2 affects differentiation and decreases proliferation of endometrial stromal sarcoma cells","volume":"5","author":"Hrzenjak","year":"2006","journal-title":"Mol Cancer Ther"},{"issue":"19","key":"10.1016\/j.bcp.2019.113698_b0225","doi-asserted-by":"crossref","first-page":"13548","DOI":"10.1074\/jbc.M510023200","article-title":"Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer","volume":"281","author":"Wilson","year":"2006","journal-title":"J Biol Chem"},{"issue":"19","key":"10.1016\/j.bcp.2019.113698_b0230","doi-asserted-by":"crossref","first-page":"8415","DOI":"10.1128\/MCB.25.19.8415-8429.2005","article-title":"Tumor suppressor SMAR1 mediates cyclin D1 repression by recruitment of the SIN3\/histone deacetylase 1 complex","volume":"25","author":"Rampalli","year":"2005","journal-title":"Mol Cell Biol"},{"issue":"1","key":"10.1016\/j.bcp.2019.113698_b0235","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3390\/cancers7010030","article-title":"p53 Acetylation: Regulation and Consequences","volume":"7","author":"Reed","year":"2014","journal-title":"Cancers (Basel)"},{"issue":"31","key":"10.1016\/j.bcp.2019.113698_b0240","doi-asserted-by":"crossref","first-page":"32620","DOI":"10.1074\/jbc.M402691200","article-title":"Restoration of transforming growth factor-beta signaling through receptor RI induction by histone deacetylase activity inhibition in breast cancer cells","volume":"279","author":"Ammanamanchi","year":"2004","journal-title":"J Biol Chem"},{"issue":"7","key":"10.1016\/j.bcp.2019.113698_b0245","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1038\/sj.leu.2403367","article-title":"Acute promyelocytic leukemia: PML\/RARalpha and the leukemic stem cell","volume":"18","author":"Puccetti","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.bcp.2019.113698_b0250","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.2741\/3977","article-title":"RUNX1 and RUNX1-ETO: roles in hematopoiesis and leukemogenesis","volume":"17","author":"Lam","year":"2012","journal-title":"Front Biosci (Landmark Ed)"},{"issue":"2","key":"10.1016\/j.bcp.2019.113698_b0255","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/ijc.23094","article-title":"Protein kinase CK2 is a key activator of histone deacetylase in hypoxia-associated tumors","volume":"122","author":"Pluemsampant","year":"2008","journal-title":"Int J Cancer"},{"issue":"4","key":"10.1016\/j.bcp.2019.113698_b0260","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.molcel.2005.04.006","article-title":"Regulation of tissue-specific and extracellular matrix-related genes by a class I histone deacetylase","volume":"18","author":"Whetstine","year":"2005","journal-title":"Mol Cell"},{"issue":"1","key":"10.1016\/j.bcp.2019.113698_b0265","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1128\/MCB.24.1.306-319.2004","article-title":"Snail mediates E-cadherin repression by the recruitment of the Sin3A\/histone deacetylase 1 (HDAC1)\/HDAC2 complex","volume":"24","author":"Peinado","year":"2004","journal-title":"Mol Cell Biol"},{"issue":"20","key":"10.1016\/j.bcp.2019.113698_b0270","doi-asserted-by":"crossref","first-page":"7561","DOI":"10.1128\/MCB.00605-06","article-title":"Peroxisome proliferator-activated receptor gamma regulates E-cadherin expression and inhibits growth and invasion of prostate cancer","volume":"26","author":"Annicotte","year":"2006","journal-title":"Mol Cell Biol"},{"issue":"4","key":"10.1016\/j.bcp.2019.113698_b0275","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1046\/j.1365-2141.2002.03955.x","article-title":"Histone deacetylase inhibitors potently repress CXCR4 chemokine receptor expression and function in acute lymphoblastic leukaemia","volume":"119","author":"Crazzolara","year":"2002","journal-title":"Br J Haematol"},{"issue":"22","key":"10.1016\/j.bcp.2019.113698_b0280","doi-asserted-by":"crossref","first-page":"10770","DOI":"10.1158\/0008-5472.CAN-06-1609","article-title":"Epigenetic regulation of tumor endothelial cell anergy: silencing of intercellular adhesion molecule-1 by histone modifications","volume":"66","author":"Hellebrekers","year":"2006","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.bcp.2019.113698_b0285","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1111\/febs.12079","article-title":"Histone deacetylase 6 plays a role as a distinct regulator of diverse cellular processes","volume":"280","author":"Li","year":"2013","journal-title":"The FEBS journal"},{"issue":"6","key":"10.1016\/j.bcp.2019.113698_b0290","doi-asserted-by":"crossref","first-page":"233","DOI":"10.5582\/ddt.2013.v7.6.233","article-title":"HDAC6: physiological function and its selective inhibitors for cancer treatment","volume":"7","author":"Yang","year":"2013","journal-title":"Drug discoveries & therapeutics"},{"issue":"11","key":"10.1016\/j.bcp.2019.113698_b0295","doi-asserted-by":"crossref","DOI":"10.3390\/molecules21111608","article-title":"Natural Compound Histone Deacetylase Inhibitors (HDACi): Synergy with Inflammatory Signaling Pathway Modulators and Clinical Applications in Cancer","volume":"21","author":"Losson","year":"2016","journal-title":"Molecules"},{"issue":"6","key":"10.1016\/j.bcp.2019.113698_b0300","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1016\/j.ejmech.2010.02.030","article-title":"Inside HDAC with HDAC inhibitors","volume":"45","author":"Bertrand","year":"2010","journal-title":"European journal of medicinal chemistry"},{"key":"10.1016\/j.bcp.2019.113698_b0305","first-page":"1","article-title":"Synthesis, Enzyme Assays and Molecular Docking Studies of Fluorinated Bioisosteres of Santacruzamate A as Potential HDAC Tracers","volume":"13","author":"Ahamed","year":"2016","journal-title":"Letters in Drug Design & Discovery"},{"issue":"10","key":"10.1016\/j.bcp.2019.113698_b0310","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20102415","article-title":"p53 at the Crossroads between Different Types of HDAC Inhibitor-Mediated Cancer Cell Death","volume":"20","author":"Mrakovcic","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10.1016\/j.bcp.2019.113698_b0315","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1101\/gr.5540007","article-title":"Butyrate mediates decrease of histone acetylation centered on transcription start sites and down-regulation of associated genes","volume":"17","author":"Rada-Iglesias","year":"2007","journal-title":"Genome Res"},{"issue":"5","key":"10.1016\/j.bcp.2019.113698_b0320","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.leukres.2005.08.023","article-title":"Transcriptional and post-transcriptional regulation of glutathione S-transferase P1 expression during butyric acid-induced differentiation of K562 cells","volume":"30","author":"Schnekenburger","year":"2006","journal-title":"Leukemia research"},{"issue":"3","key":"10.1016\/j.bcp.2019.113698_b0325","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1002\/ijc.22558","article-title":"Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (Vorinostat, SAHA) profoundly inhibits the growth of human pancreatic cancer cells","volume":"121","author":"Kumagai","year":"2007","journal-title":"Int J Cancer"},{"issue":"6","key":"10.1016\/j.bcp.2019.113698_b0330","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1158\/1940-6207.CAPR-08-0142","article-title":"3,3'-diindolylmethane enhances the efficacy of butyrate in colon cancer prevention through down-regulation of survivin","volume":"2","author":"Bhatnagar","year":"2009","journal-title":"Cancer prevention research"},{"issue":"12","key":"10.1016\/j.bcp.2019.113698_b0335","doi-asserted-by":"crossref","first-page":"3956","DOI":"10.1158\/1078-0432.CCR-10-3412","article-title":"Vorinostat-induced apoptosis in mantle cell lymphoma is mediated by acetylation of proapoptotic BH3-only gene promoters","volume":"17","author":"Xargay-Torrent","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.bcp.2019.113698_b0340","doi-asserted-by":"crossref","first-page":"3285","DOI":"10.1158\/1535-7163.MCT-08-0385","article-title":"Role of histone deacetylase inhibitor-induced reactive oxygen species and DNA damage in LAQ-824\/fludarabine antileukemic interactions","volume":"7","author":"Rosato","year":"2008","journal-title":"Mol Cancer Ther"},{"issue":"37","key":"10.1016\/j.bcp.2019.113698_b0345","doi-asserted-by":"crossref","first-page":"5541","DOI":"10.1038\/sj.onc.1210620","article-title":"Histone deacetylase inhibitors: molecular mechanisms of action","volume":"26","author":"Xu","year":"2007","journal-title":"Oncogene"},{"issue":"9","key":"10.1016\/j.bcp.2019.113698_b0350","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nsmb.1899","article-title":"Human HDAC1 and HDAC2 function in the DNA-damage response to promote DNA nonhomologous end-joining","volume":"17","author":"Miller","year":"2010","journal-title":"Nat Struct Mol Biol"},{"issue":"4","key":"10.1016\/j.bcp.2019.113698_b0355","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1158\/1535-7163.MCT-09-0988","article-title":"Treatment with panobinostat induces glucose-regulated protein 78 acetylation and endoplasmic reticulum stress in breast cancer cells","volume":"9","author":"Rao","year":"2010","journal-title":"Mol Cancer Ther"},{"issue":"7","key":"10.1016\/j.bcp.2019.113698_b0360","doi-asserted-by":"crossref","first-page":"3773","DOI":"10.1158\/0008-5472.CAN-05-2961","article-title":"Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells","volume":"66","author":"Nawrocki","year":"2006","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.bcp.2019.113698_b0365","doi-asserted-by":"crossref","first-page":"819","DOI":"10.4161\/auto.23908","article-title":"The emerging role of acetylation in the regulation of autophagy","volume":"9","author":"Banreti","year":"2013","journal-title":"Autophagy"},{"issue":"7","key":"10.1016\/j.bcp.2019.113698_b0370","doi-asserted-by":"crossref","first-page":"745","DOI":"10.2174\/1568026615666150825141330","article-title":"Epigenetic alterations as a universal feature of cancer hallmarks and a promising target for personalized treatments","volume":"16","author":"Schnekenburger","year":"2016","journal-title":"Current topics in medicinal chemistry"},{"key":"10.1016\/j.bcp.2019.113698_b0375","first-page":"47","article-title":"Misfolded proteins: from little villains to little helpers in the fight against cancer","volume":"5","author":"Bruning","year":"2015","journal-title":"Frontiers in oncology"},{"issue":"3","key":"10.1016\/j.bcp.2019.113698_b0380","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/0092-8674(75)90107-5","article-title":"Butyric acid, a potent inducer of erythroid differentiation in cultured erythroleukemic cells","volume":"5","author":"Leder","year":"1975","journal-title":"Cell"},{"issue":"9","key":"10.1016\/j.bcp.2019.113698_b0385","doi-asserted-by":"crossref","first-page":"3319","DOI":"10.1182\/blood-2002-02-0567","article-title":"The histone deacetylase inhibitor AN-9 has selective toxicity to acute leukemia and drug-resistant primary leukemia and cancer cell lines","volume":"100","author":"Batova","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2019.113698_b0390","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/479364","article-title":"Molecular and therapeutic potential and toxicity of valproic acid","volume":"2010","author":"Chateauvieux","year":"2010","journal-title":"Journal of biomedicine & biotechnology"},{"issue":"6","key":"10.1016\/j.bcp.2019.113698_b0395","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.3892\/ijmm.2016.2552","article-title":"Valproic acid enhances the antileukemic effect of cytarabine by triggering cell apoptosis","volume":"37","author":"Liu","year":"2016","journal-title":"International journal of molecular medicine"},{"issue":"3","key":"10.1016\/j.bcp.2019.113698_b0400","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1158\/1078-0432.CCR-10-0738","article-title":"Phase 1 study of valproic acid in pediatric patients with refractory solid or CNS tumors: a children's oncology group report","volume":"17","author":"Su","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.bcp.2019.113698_b0405","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/j.1365-2141.2009.07881.x","article-title":"Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia","volume":"147","author":"Blum","year":"2009","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.bcp.2019.113698_b0410","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1097\/CMR.0b013e328307c248","article-title":"Multicenter phase II trial of the histone deacetylase inhibitor pyridylmethyl-N-{4-[(2-aminophenyl)-carbamoyl]-benzyl}-carbamate in pretreated metastatic melanoma","volume":"18","author":"Hauschild","year":"2008","journal-title":"Melanoma research"},{"issue":"5","key":"10.1016\/j.bcp.2019.113698_b0415","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.leukres.2007.09.007","article-title":"Potentiation of reactive oxygen species is a marker for synergistic cytotoxicity of MS-275 and 5-azacytidine in leukemic cells","volume":"32","author":"Gao","year":"2008","journal-title":"Leukemia research"},{"issue":"1","key":"10.1016\/j.bcp.2019.113698_b0420","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1182\/blood-2006-06-025999","article-title":"Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)","volume":"109","author":"Duvic","year":"2007","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.bcp.2019.113698_b0425","doi-asserted-by":"crossref","first-page":"7138","DOI":"10.1158\/1078-0432.CCR-08-0122","article-title":"A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California Cancer Consortium study","volume":"14","author":"Luu","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.bcp.2019.113698_b0430","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1097\/JTO.0b013e3181952478","article-title":"Vorinostat (NSC# 701852) in patients with relapsed non-small cell lung cancer: a Wisconsin Oncology Network phase II study","volume":"4","author":"Traynor","year":"2009","journal-title":"Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer"},{"issue":"2","key":"10.1016\/j.bcp.2019.113698_b0435","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ygyno.2008.01.009","article-title":"Gynecologic Oncology, A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study","volume":"109","author":"Modesitt","year":"2008","journal-title":"Gynecologic oncology"},{"issue":"1","key":"10.1016\/j.bcp.2019.113698_b0440","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1210\/jc.2008-1631","article-title":"Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma","volume":"94","author":"Woyach","year":"2009","journal-title":"The Journal of clinical endocrinology and metabolism"},{"key":"10.1016\/j.bcp.2019.113698_b0445","first-page":"1971","article-title":"Profile of belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma","volume":"7","author":"Bodiford","year":"2014","journal-title":"OncoTargets and therapy"},{"issue":"2","key":"10.1016\/j.bcp.2019.113698_b0450","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.canlet.2009.02.019","article-title":"Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges","volume":"280","author":"Atadja","year":"2009","journal-title":"Cancer letters"},{"issue":"7","key":"10.1016\/j.bcp.2019.113698_b0455","doi-asserted-by":"crossref","first-page":"441","DOI":"10.2146\/ajhp150487","article-title":"Panobinostat: A histone deacetylase inhibitor for the treatment of relapsed or refractory multiple myeloma","volume":"73","author":"Wahaib","year":"2016","journal-title":"American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists"},{"issue":"15","key":"10.1016\/j.bcp.2019.113698_b0460","doi-asserted-by":"crossref","first-page":"4628","DOI":"10.1158\/1078-0432.CCR-06-0511","article-title":"A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies","volume":"12","author":"Giles","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.bcp.2019.113698_b0465","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/JTO.0b013e318191520c","article-title":"Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma","volume":"4","author":"Ramalingam","year":"2009","journal-title":"Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer"},{"issue":"3","key":"10.1016\/j.bcp.2019.113698_b0470","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1158\/1078-0432.CCR-07-1786","article-title":"A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors","volume":"14","author":"Steele","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"29","key":"10.1016\/j.bcp.2019.113698_b0475","doi-asserted-by":"crossref","first-page":"4485","DOI":"10.1200\/JCO.2010.28.9066","article-title":"Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma","volume":"28","author":"Whittaker","year":"2010","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.bcp.2019.113698_b0480","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20092271","article-title":"HDAC1,2 Knock-Out and HDACi Induced Cell Apoptosis in Imatinib-Resistant K562 Cells","volume":"20","author":"Chen","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.bcp.2019.113698_b0485","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1124\/jpet.107.124461","article-title":"Bcr-Abl-independent imatinib-resistant K562 cells show aberrant protein acetylation and increased sensitivity to histone deacetylase inhibitors","volume":"322","author":"Lee","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.bcp.2019.113698_b0490","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.lfs.2018.09.040","article-title":"Synergistic activity of imatinib and AR-42 against chronic myeloid leukemia cells mainly through HDAC1 inhibition","volume":"211","author":"Wei","year":"2018","journal-title":"Life Sci"},{"issue":"5","key":"10.1016\/j.bcp.2019.113698_b0495","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1111\/bjh.14739","article-title":"Research on the epigenetic regulation mechanism of the PTPN6 gene in advanced chronic myeloid leukaemia","volume":"178","author":"Zhang","year":"2017","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1016\/j.bcp.2019.113698_b0500","doi-asserted-by":"crossref","first-page":"3236","DOI":"10.1182\/blood-2002-08-2675","article-title":"Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells","volume":"101","author":"Nimmanapalli","year":"2003","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.bcp.2019.113698_b0505","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0174107","article-title":"The HDAC inhibitor SB939 overcomes resistance to BCR-ABL kinase Inhibitors conferred by the BIM deletion polymorphism in chronic myeloid leukemia","volume":"12","author":"Rauzan","year":"2017","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.bcp.2019.113698_b0510","doi-asserted-by":"crossref","DOI":"10.1002\/mgg3.613","article-title":"Sodium butyrate and panobinostat induce apoptosis of chronic myeloid leukemia cells via multiple pathways","volume":"7","author":"Jia","year":"2019","journal-title":"Mol Genet Genomic Med"},{"issue":"3","key":"10.1016\/j.bcp.2019.113698_b0515","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1182\/blood-2007-10-116376","article-title":"Vorinostat synergistically potentiates MK-0457 lethality in chronic myelogenous leukemia cells sensitive and resistant to imatinib mesylate","volume":"112","author":"Dai","year":"2008","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.bcp.2019.113698_b0520","doi-asserted-by":"crossref","first-page":"6106","DOI":"10.1158\/1078-0432.CCR-08-0721","article-title":"Cotreatment with vorinostat enhances activity of MK-0457 (VX-680) against acute and chronic myelogenous leukemia cells","volume":"14","author":"Fiskus","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.bcp.2019.113698_b0525","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1111\/cas.12965","article-title":"Combination of panobinostat with ponatinib synergistically overcomes imatinib-resistant CML cells","volume":"107","author":"Matsuda","year":"2016","journal-title":"Cancer Sci"},{"issue":"5","key":"10.1016\/j.bcp.2019.113698_b0530","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1002\/cncr.21725","article-title":"Valproate enhances imatinib-induced growth arrest and apoptosis in chronic myeloid leukemia cells","volume":"106","author":"Morotti","year":"2006","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.bcp.2019.113698_b0535","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1158\/1078-0432.CCR-11-0234","article-title":"HDAC inhibitors potentiate the activity of the BCR\/ABL kinase inhibitor KW-2449 in imatinib-sensitive or -resistant BCR\/ABL+ leukemia cells in vitro and in vivo","volume":"17","author":"Nguyen","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.bcp.2019.113698_b0540","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1182\/blood-2005-11-4639","article-title":"Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells","volume":"108","author":"Fiskus","year":"2006","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.bcp.2019.113698_b0545","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0089080","article-title":"Combining the ABL1 kinase inhibitor ponatinib and the histone deacetylase inhibitor vorinostat: a potential treatment for BCR-ABL-positive leukemia","volume":"9","author":"Okabe","year":"2014","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.bcp.2019.113698_b0550","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1097\/CAD.0b013e3280761a8a","article-title":"Combination of SK-7041, one of novel histone deacetylase inhibitors, and STI571-induced synergistic apoptosis in chronic myeloid leukemia","volume":"18","author":"Kim","year":"2007","journal-title":"Anticancer Drugs"},{"issue":"7","key":"10.1016\/j.bcp.2019.113698_b0555","doi-asserted-by":"crossref","first-page":"951","DOI":"10.4161\/cbt.28931","article-title":"SAHA and S116836, a novel tyrosine kinase inhibitor, synergistically induce apoptosis in imatinib-resistant chronic myelogenous leukemia cells","volume":"15","author":"Bu","year":"2014","journal-title":"Cancer Biol Ther"},{"issue":"19","key":"10.1016\/j.bcp.2019.113698_b0560","doi-asserted-by":"crossref","first-page":"5869","DOI":"10.1158\/1078-0432.CCR-06-0980","article-title":"Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells","volume":"12","author":"Fiskus","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.bcp.2019.113698_b0565","first-page":"94","article-title":"Novel combination treatments targeting chronic myeloid leukemia stem cells, Clinical lymphoma, myeloma","volume":"12","author":"Al Baghdadi","year":"2012","journal-title":"& leukemia"},{"issue":"2","key":"10.1016\/j.bcp.2019.113698_b0570","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.yexcr.2018.07.017","article-title":"HDAC inhibitor suppresses proliferation and tumorigenicity of drug-resistant chronic myeloid leukemia stem cells through regulation of hsa-miR-196a targeting BCR\/ABL1","volume":"370","author":"Bamodu","year":"2018","journal-title":"Exp Cell Res"},{"issue":"11","key":"10.1016\/j.bcp.2019.113698_b0575","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.7150\/thno.16139","article-title":"Depletion of gamma-catenin by Histone Deacetylase Inhibition Confers Elimination of CML Stem Cells in Combination with Imatinib","volume":"6","author":"Jin","year":"2016","journal-title":"Theranostics"},{"issue":"9","key":"10.1016\/j.bcp.2019.113698_b0580","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.3390\/ph3092751","article-title":"Clinical Toxicities of Histone Deacetylase Inhibitors","volume":"3","author":"Subramanian","year":"2010","journal-title":"Pharmaceuticals"},{"issue":"29","key":"10.1016\/j.bcp.2019.113698_b0585","doi-asserted-by":"crossref","first-page":"26729","DOI":"10.1074\/jbc.C500186200","article-title":"Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors","volume":"280","author":"Bali","year":"2005","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.bcp.2019.113698_b0590","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1089\/ars.2014.5854","article-title":"New Insights into the Connection Between Histone Deacetylases","volume":"23","author":"Chiaradonna","year":"2015","journal-title":"Cell Metabolism, and Cancer, Antioxid Redox Signal"},{"issue":"6","key":"10.1016\/j.bcp.2019.113698_b0595","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.cell.2014.07.048","article-title":"Cell-state-specific metabolic dependency in hematopoiesis and leukemogenesis","volume":"158","author":"Wang","year":"2014","journal-title":"Cell"},{"issue":"9","key":"10.1016\/j.bcp.2019.113698_b0600","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2016.78","article-title":"Aldehyde dehydrogenases inhibition eradicates leukemia stem cells while sparing normal progenitors","volume":"6","author":"Venton","year":"2016","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1016\/j.bcp.2019.113698_b0605","doi-asserted-by":"crossref","DOI":"10.4161\/onci.27414","article-title":"The anticancer effects of HDAC inhibitors require the immune system","volume":"3","author":"West","year":"2014","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.bcp.2019.113698_b0610","doi-asserted-by":"crossref","first-page":"469","DOI":"10.3389\/fimmu.2017.00469","article-title":"Immune Effector Recovery in Chronic Myeloid Leukemia and Treatment-Free Remission","volume":"8","author":"Hughes","year":"2017","journal-title":"Front Immunol"},{"issue":"7","key":"10.1016\/j.bcp.2019.113698_b0615","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.it.2017.04.004","article-title":"Mechanisms of Immune Tolerance in Leukemia and Lymphoma","volume":"38","author":"Curran","year":"2017","journal-title":"Trends Immunol"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295219303971?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295219303971?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T15:06:20Z","timestamp":1762095980000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295219303971"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":123,"alternative-id":["S0006295219303971"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2019.113698","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Epigenetic mechanisms underlying the therapeutic effects of HDAC inhibitors in chronic myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2019.113698","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"113698"}}